Adverse Reactions in Clinical Trials in Adults with Obesity or Overweight for Weight Reduction WEGOVY 2.4 mg Subcutaneous Injection Weekly Dosage WEGOVY was evaluated for safety in 3 randomized, double-blind, placebo-controlled trials that included 2,116 adult patients with obesity or overweight treated with 2.4 mg WEGOVY injection for up to 68 weeks and a 7-week off-drug follow-up period [see Clinical Studies (14.2)]
IFIS: Berkshire, UK, 2009
Portions should be roughly half of what you would normally eat
We ship from within Canada, so there are no customs delays, border holds, or international shipping complications that can degrade peptide quality or result in ceased product
And certain spices turmeric, cinnamon, cayenne have demonstrated meaningful GLP-1 effects in human studies